Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07498452
Recruiting Observational

Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others

NCT07498452 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-05-06
Last updated
2026-03-27

Condition(s) studied

REM Sleep Behavior DisorderIsolated REM Sleep Behavior Disorder

Study summary

The goal of this observational study is to explore the unmet needs and the psychosocial impact of isolated REM Sleep Behavior Disorder (iRBD) on patients and their significant others. Isolated REM Sleep Behavior Disorder is a sleep disorder characterized by dream-enactment behaviors during REM sleep and is increasingly recognized as a prodromal condition associated with neurodegenerative diseases. Despite growing clinical attention, little is known about the informational, emotional, and practical needs experienced by patients and their caregivers.

The main questions this study aims to answer are:

What are the main unmet informational, psychological, and clinical needs reported by patients with isolated REM Sleep Behavior Disorder?

What are the main challenges and support needs experienced by their significant others or caregivers?

How does the diagnosis of iRBD affect quality of life, emotional well-being, and perceptions of future health risks for both patients and caregivers?

This is a multicenter cross-sectional observational study conducted in several sleep and movement disorders centers. The study aims to collect structured information directly from patients and their significant others in order to better understand their experiences, concerns, and expectations regarding the disease and its management.

Participants will be asked to:

complete an online questionnaire about their experience with isolated REM Sleep Behavior Disorder, including perceived needs, access to information, and interactions with healthcare services;

report information about emotional well-being, quality of life, and concerns related to the possible future progression of the disorder;

caregivers or significant others will complete a parallel questionnaire focused on their experiences, caregiving burden, informational needs, and perceived support.

The information collected in this study will help clinicians and researchers better understand the real-world needs of individuals living with isolated REM Sleep Behavior Disorder and their families. The results may contribute to improving patient education, clinical care pathways, and support services for this population.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with iRBD according to the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria. * Patients who have had a follow-up visit within the previous 12 months. * Patients who provide informed consent to participate in the study. * Partners/family members of patients with iRBD who accept to participate. Exclusion Criteria: * Patients with RBD who have already phenoconverted to a neurodegenerative disorder. * Patients or partners/family members without access to an email address.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Emilia-Romagna Recruiting
IRCCS Ospedale Policlinico San Martino Genoa Liguria Recruiting
IRCCS Ospedale San Raffaele Milan Lombardy Recruiting
Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS Pavia Lombardy Recruiting
Azienda Ospedaliero-Universitaria di Cagliari Cagliari Sardinia Recruiting
I.R.C.C.S. Associazione Oasi Maria SS. - Ospedale Classificato Troina Sicily Recruiting
Azienda Ospedaliero Universitaria Pisana Pisa Tuscany Recruiting
Azienda Ospedaliera Universitaria Integrata Verona Verona Veneto Recruiting

More Universita di Verona trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07498452 on ClinicalTrials.gov ↗ ← All trials in Italy